Medical technologies addressing women’s health represent one of healthcare’s most historically underserved and rapidly evolving sectors. The category spans fertility and assisted reproduction, pregnancy and maternal care, menstrual health, menopause, pelvic health, gynecological diagnostics, digital therapeutics, and connected medical technologies.
For decades, innovation was constrained by systemic underinvestment, with only a small fraction of healthcare R&D focused on female-specific conditions. This gap is now creating significant opportunities for companies addressing unmet clinical needs. The global FemTech market is projected to exceed $250 billion by 2035, driven by advances across diagnostics, devices, digital health platforms, and personalized care solutions.
Investment momentum is accelerating as healthcare systems and investors recognize the scale of the opportunity. Silicon Valley Bank reported $2.6 billion in women’s health venture funding in 2024, while Flo Health’s $1 billion valuation following its Series C round demonstrated that the category is capable of producing globally scalable healthcare companies.
The businesses leading this space increasingly operate across medical devices, diagnostics, digital health, and consumer healthcare simultaneously. Scaling successfully requires leaders who can navigate regulatory complexity, establish clinical credibility, build evidence-driven commercial strategies, and engage a patient population demanding a new standard of healthcare innovation.